Observe Real-life Allocation of Atypical Antipsychotics in the Acute Inpatient Management of Schizophrenia

NCT ID: NCT01544608

Last Updated: 2013-06-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1076 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-07-31

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this Non- Interventional Study (NIS) is to describe the use of atypical antipsychotics in subjects with Schizophrenia during the hospitalisation due to acute psychotic episode by evaluation of drug, dose and mode of administration of the medication.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

RECONNECT-S BETA

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Subjects who are hospitalized due to acute psychotic episode.

All subjects who are hospitalized due to acute psychotic episode. The subjects should be managed according to normal clinical practice until discharge time.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Meet the diagnostic criteria for schizophrenia stated in The Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria.
* Subject is hospitalised due to an acute psychotic episode.
* Ability of the subject to understand and comply with the requirements of the study, as judged by the investigator.

Exclusion Criteria

* Current participation in any clinical trial.
* Previous enrolment in the present NIS (in case of recurrence occurred during the enrolment period).
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Talaat Matar, CONSULTANT PSYCHIATRIST

Role: STUDY_CHAIR

Obaid Alla Hospital,Ras Al Khaima,UAE

Tarek Darwish, CONSULTANT PSYCHIATRIST

Role: STUDY_CHAIR

Sheikh Khalifa Medical City(SKMC), Abudhabi,UAE

Sohail Khan, CONSULTANT PSYCHIATRIST

Role: STUDY_CHAIR

Jeddah Psychiatric hospital,Jeddah, Saudi Arabia

Tarek Okasha, PROFESSOR

Role: STUDY_CHAIR

Ain Shams University, Cairo, Egypt

Mohamed Nasr, PROFESSOR

Role: STUDY_CHAIR

Cairo University, Egypt

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Cairo, , Egypt

Site Status

Research Site

Dammam, , Saudi Arabia

Site Status

Research Site

Jeddah, , Saudi Arabia

Site Status

Research Site

Riyadh, , Saudi Arabia

Site Status

Research Site

Abu Dhabi, , United Arab Emirates

Site Status

Research Site

Dubai, , United Arab Emirates

Site Status

Research Site

Ras al-Khaimah, , United Arab Emirates

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt Saudi Arabia United Arab Emirates

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NIS-NME-XXX-2011/1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.